Abstract
Introduction of gene therapy into molecular medicine has been gaining increasing interest. Although treatment of various diseases e.g. monogenetic defects or cancer by using gene transfer technologies has been extensively probed, the clinical success has been limited. However, recent experimental data suggest that gene therapy may represent an attractive and powerful approach in preventing ischemia / reperfusion injury as well as organ rejection in transplant recipients. Easy and selective access to the donor organ facilitates the reduction of potentially harmful systemic side effects of gene therapy vectors. By introducing anti-apoptotic or cytoprotective genes, these studies focused on the protection of the transplant from the apoptotic cell death. In addition, down-regulation of adhesion molecules and / or blockade of gene expression in the graft itself also ameliorated ischemia / reperfusion injury. This review summarizes the current progress on gene therapy application in combating ischemia-reperfusion injury in organ transplantation. Although the use of viral vectors is emphasized, non-viral gene transfer techniques are also discussed. Future development of novel, low-immunogenic vectors should further contribute to the minimization of ischemia / reperfusion injury, and thus to the overall success of organ transplantation.
Keywords: gene therapy, transplantation, ischemia/reperfusion injury, viral vectors, anti-apoptotic genes, cytoprotective genes
Current Gene Therapy
Title: Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Volume: 5 Issue: 1
Author(s): T. Ritter and J. W. Kupiec-Weglinski
Affiliation:
Keywords: gene therapy, transplantation, ischemia/reperfusion injury, viral vectors, anti-apoptotic genes, cytoprotective genes
Abstract: Introduction of gene therapy into molecular medicine has been gaining increasing interest. Although treatment of various diseases e.g. monogenetic defects or cancer by using gene transfer technologies has been extensively probed, the clinical success has been limited. However, recent experimental data suggest that gene therapy may represent an attractive and powerful approach in preventing ischemia / reperfusion injury as well as organ rejection in transplant recipients. Easy and selective access to the donor organ facilitates the reduction of potentially harmful systemic side effects of gene therapy vectors. By introducing anti-apoptotic or cytoprotective genes, these studies focused on the protection of the transplant from the apoptotic cell death. In addition, down-regulation of adhesion molecules and / or blockade of gene expression in the graft itself also ameliorated ischemia / reperfusion injury. This review summarizes the current progress on gene therapy application in combating ischemia-reperfusion injury in organ transplantation. Although the use of viral vectors is emphasized, non-viral gene transfer techniques are also discussed. Future development of novel, low-immunogenic vectors should further contribute to the minimization of ischemia / reperfusion injury, and thus to the overall success of organ transplantation.
Export Options
About this article
Cite this article as:
Ritter T. and Kupiec-Weglinski W. J., Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation, Current Gene Therapy 2005; 5 (1) . https://dx.doi.org/10.2174/1566523052997451
DOI https://dx.doi.org/10.2174/1566523052997451 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Oxidative Stress and Pathways of Molecular Hydrogen Effects in Medicine
Current Pharmaceutical Design MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Pathomechanisms of Myocardial Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle
Current Pharmaceutical Design Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Cardioprotection with opioids - Trusted old friends -Clinical Science -
Current Pharmaceutical Design Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Novel Therapeutics in Glaucoma Management
Current Neuropharmacology Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology The Redox Regulation of Thiol Dependent Signaling Pathways in Cancer
Current Pharmaceutical Design Potential for Discovery of Neuroprotective Factors in Serum and Tissue from Hibernating Species
Mini-Reviews in Medicinal Chemistry Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry